The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Browse trials for

• Diabetes Mellitus 10,925
• Diabetes Mellitus, Type 2 9,359

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 665 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.

Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.

Study arms

• Experimental
  Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg

  Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).

  Drug: liraglutide · Drug: metformin

• Experimental
  Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg

  Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).

  Drug: metformin · Drug: liraglutide

• Active comparator
  Sita -> Sita

  Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).

  Drug: sitagliptin · Drug: metformin

• Experimental
  Sita -> Sita -> Lira 1.2 mg

  Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.

  Drug: liraglutide · Drug: sitagliptin · Drug: metformin

• Experimental
  Sita -> Sita -> Lira 1.8 mg

  Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.

  Drug: sitagliptin · Drug: metformin · Drug: liraglutide

Interventions

• Drugliraglutide

  1.2 mg once daily, subcutaneous (under the skin) injection

• Drugsitagliptin

  Tablets, 100 mg daily

• Drugmetformin

  Tablets, minimum 1500 mg daily

• Drugliraglutide

  1.8 mg once daily, subcutaneous (under the skin) injection

Primary outcomes

1. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

   Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

   Time frame: Week 0, Week 26

2. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

   Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 52.

   Time frame: Week 0, Week 52

3. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78

   Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 78.

   Time frame: Week 0, Week 78

4. Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78

   Mean Change in Glycosylated Haemoglobin A1c (HbA1c) from Week 52 to Week 78

   Time frame: Week 52, Week 78

Secondary outcomes

1. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26

   Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26

   Time frame: Week 0, Week 26

2. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 52

   Time frame: Week 0, Week 52

3. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 78. Based on the FAS.

   Time frame: Week 0, Week 78

4. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 78. Based on the extension 2 FAS.

   Time frame: Week 0, Week 78

5. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26

   Calculated as the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 26

   Time frame: Week 0, Week 26

6. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 52

   Time frame: Week 0, Week 52

7. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 78. Based on the FAS.

   Time frame: Week 0, Week 78

8. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

   Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =\< 6.5% at Week 78. Based on the extension 2 FAS.

   Time frame: Week 0, Week 78

9. Mean Change From Baseline in Body Weight at Week 26

   Calculated as an estimate of the mean change from baseline in body weight at Week 26.

   Time frame: Week 0, Week 26

10. Mean Change From Baseline in Body Weight at Week 52

    Calculated as an estimate of the mean change from baseline in body weight at Week 52.

    Time frame: Week 0, Week 52

11. Mean Change in Body Weight From Week 52 to Week 78

    Mean change in body weight from Week 52 to Week 78.

    Time frame: Week 52, Week 78

12. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

    Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 26.

    Time frame: Week 0, Week 26

13. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

    Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 52.

    Time frame: Week 0, Week 52

14. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78

    Calculated as an estimate of the mean change in fasting plasma glucose (FPG) from baseline to Week 78.

    Time frame: Week 0, Week 78

15. Mean Change in Fasting Plasma Glucose (FPG) From Week 52 to Week 78

    Mean change in fasting plasma glucose (FPG) Week 52 to Week 78.

    Time frame: Week 52, Week 78

16. Mean Change From Baseline in Beta-cell Function at Week 26

    Calculated as an estimate of the mean change from baseline in beta-cell function at Week 26. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

    Time frame: Week 0, Week 26

17. Mean Change From Baseline in Beta-cell Function at Week 52

    Calculated as an estimate of the mean change from baseline in beta-cell function at Week 52. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

    Time frame: Week 0, Week 52

18. Mean Change in Beta-cell Function From Week 52 to Week 78

    Mean change in beta-cell function from Week 52 to Week 78. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

    Time frame: Week 52, Week 78

19. Mean Change From Baseline in Total Cholesterol at Week 26

    Calculated as an estimate of the mean change from baseline in total cholesterol at Week 26.

    Time frame: Week 0, Week 26

20. Mean Change From Baseline in Total Cholesterol at Week 52

    Calculated as an estimate of the mean change from baseline in total cholesterol at Week 52.

    Time frame: Week 0, Week 52

21. Mean Change in Total Cholesterol From Week 52 to Week 78

    Mean change in total cholesterol from Week 52 to Week 78

    Time frame: Week 52, Week 78

22. Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26

    Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 26.

    Time frame: Week 0, Week 26

23. Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52

    Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 52.

    Time frame: Week 0, Week 52

24. Mean Change in Low-density Lipoprotein-cholesterol (LDL-C) From Week 52 to Week 78

    Mean change in low-density lipoprotein-cholesterol (LDL-C) from week 52 to Week 78.

    Time frame: Week 52, Week 78

25. Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26

    Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 26.

    Time frame: Week 0, Week 26

26. Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52

    Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 52.

    Time frame: Week 0, Week 52

27. Mean Change in High-density Lipoprotein-cholesterol (HDL-C) From Week 52 to Week 78

    Mean change in high-density lipoprotein-cholesterol (HDL-C) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

28. Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26

    Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 26.

    Time frame: Week 0, Week 26

29. Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52

    Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 52.

    Time frame: Week 0, Week 52

30. Mean Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52 to Week 78

    Mean change in very low-density lipoprotein-cholesterol (VLDL-C) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

31. Mean Change From Baseline in Triglycerides (TG) at Week 26

    Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 26.

    Time frame: Week 0, Week 26

32. Mean Change From Baseline in Triglycerides (TG) at Week 52

    Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 52.

    Time frame: Week 0, Week 52

33. Mean Change in Triglycerides (TG) From Week 52 to Week 78

    Mean change in triglycerides (TG) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

34. Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26

    Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 26.

    Time frame: Week 0, Week 26

35. Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52

    Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 52.

    Time frame: Week 0, Week 52

36. Mean Change in Free Fatty Acids (FFA) From Week 52 to Week 78

    Mean change in free fatty acids (FFA) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

37. Mean Change From Baseline in Apolipoprotein B at Week 26

    Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 26.

    Time frame: Week 0, Week 26

38. Mean Change From Baseline in Apolipoprotein B at Week 52

    Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 52.

    Time frame: Week 0, Week 52

39. Mean Change in Apolipoprotein B From Week 52 to Week 78

    Mean change in apolipoprotein B (ApoB) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

40. Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26

    Calculated as an estimate of the mean change from baseline in highly sensitive C-reactive protein (hsCRP) at week 26.

    Time frame: Week 0, Week 26

41. Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26.

    Calculated as an estimate of the mean change from baseline in plasminogen activator inhibitor-1 (PAI-1) at Week 26.

    Time frame: Week 0, Week 26

42. Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26.

    Calculated as an estimate of the mean change from baseline in interleukin-6 (IL-6) at Week 26.

    Time frame: Week 0, Week 26

43. Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.

    Calculated as an estimate of the mean change from baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.

    Time frame: Week 0, Week 26

44. Mean Change From Baseline in Adiponectin at Week 26.

    Calculated as an estimate of the mean change from baseline in Adiponectin at Week 26.

    Time frame: Week 0, Week 26

45. Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.

    Calculated as an estimate of the mean change from baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.

    Time frame: Week 0, Week 26

46. Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26.

    Calculated as an estimate of the mean change from baseline in von Willebrand Factor (vWf) at Week 26. vWf is a blood glycoprotein involved in haemostasis.

    Time frame: Week 0, Week 26

47. Mean Change From Baseline in Waist to Hip Ratio at Week 26.

    Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 26. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

    Time frame: Week 0, Week 26

48. Mean Change From Baseline in Waist to Hip Ratio at Week 52

    Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 52. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

    Time frame: Week 0, Week 52

49. Mean Change in Waist to Hip Ratio From Week 52 to Week 78

    Mean change in Waist to Hip Ratio from Week 52 to Week 78. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

    Time frame: Week 52, Week 78

50. Mean Change From Baseline in Waist Circumference at Week 26.

    Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 26

    Time frame: Week 0, Week 26

51. Mean Change From Baseline in Waist Circumference at Week 52

    Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 52.

    Time frame: Week 0, Week 52

52. Mean Change in Waist Circumference From Week 52 to Week 78

    Mean change in Waist Circumference from Week 52 to Week 78.

    Time frame: Week 52, Week 78

53. Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26

    Calculated as an estimate of the mean change from baseline in Systolic Blood Pressure (SBP) at Week 26

    Time frame: Week 0, Week 26

54. Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

    Calculated as an estimate of the mean change from baseline in systolic blood pressure (SBP) at Week 52.

    Time frame: Week 0, Week 52

55. Mean Change in Systolic Blood Pressure (SBP) From Week 52 to Week 78

    Mean change in systolic blood pressure (SBP) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

56. Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26

    Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 26.

    Time frame: Week 0, Week 26

57. Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52

    Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 52.

    Time frame: Week 0, Week 52

58. Mean Change in Diastolic Blood Pressure (DBP) From Week 52 to Week 78

    Mean change in diastolic blood pressure (DBP) from Week 52 to Week 78.

    Time frame: Week 52, Week 78

59. Mean Change From Baseline in Pulse at Week 26

    Calculated as an estimate of the mean change from baseline in pulse at Week 26.

    Time frame: Week 0, Week 26

60. Mean Change From Baseline in Pulse at Week 52

    Calculated as an estimate of the mean change from baseline in pulse at Week 52.

    Time frame: Week 0, Week 52

61. Mean Change in Pulse From Week 52 to Week 78

    Mean change in pulse from Week 52 to Week 78.

    Time frame: Week 52, Week 78

62. Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

    Time frame: Week 0, Week 26

63. Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

    Time frame: Week 0, Week 52

64. Mean Change in Overall Treatment Satisfaction (OTS) From Week 52 to Week 78

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

    Time frame: Week 52, Week 78

65. Hypoglyceamic Episodes, Weeks 0-26

    Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-26

66. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26

    Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-26

67. Hypoglyceamic Episodes, Weeks 0-52

    Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-52

68. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-52

    Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-52

69. Hypoglyceamic Episodes, Weeks 0-78

    Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-78

70. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-78

    Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Weeks 0-78

71. Hypoglycaamic Episodes, Weeks 52-78

    Number of hypoglycaemic episodes from Week 52 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

    Time frame: Week 52-78

Baseline characteristics

Publications

• Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. Erratum In: Lancet. 2010 Jul 24;376(9737):234. PubMed 20417856 ↗
• Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med. 2011 Mar;28(3):333-7. doi: 10.1111/j.1464-5491.2010.03074.x. PubMed 21309842 ↗
• Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011 Apr;65(4):397-407. doi: 10.1111/j.1742-1241.2011.02656.x. Epub 2011 Mar 1. PubMed 21355967 ↗
• Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011 Nov-Dec;17(6):906-13. doi: 10.4158/ep.17.6.906. PubMed 22193143 ↗
• Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012 Jan;14(1):77-82. doi: 10.1111/j.1463-1326.2011.01493.x. Epub 2011 Oct 30. PubMed 21883806 ↗
• Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012 Mar;29(3):313-20. doi: 10.1111/j.1464-5491.2011.03429.x. PubMed 21883438 ↗
• Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M; 1860-LIRA-DPP-4 Study Group. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012 Oct;35(10):1986-93. doi: 10.2337/dc11-2113. Epub 2012 Jul 30. PubMed 22851600 ↗
• Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13. PubMed 22834986 ↗
• Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. Epub 2012 Sep 9. PubMed 22862847 ↗
• Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23. PubMed 23010561 ↗
• King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR. PubMed 23186975 ↗
• Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Erratum In: Diabetes Care. 2015 Aug;38(8):1622. doi: 10.2337/dc15-er08. PubMed 25504028 ↗
• Davidson JA, Orsted DD, Campos C. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials. Diabetes Obes Metab. 2016 Jul;18(7):725-8. doi: 10.1111/dom.12653. Epub 2016 Apr 28. PubMed 26936426 ↗
• Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013 Apr;19(3):237-46. doi: 10.18553/jmcp.2013.19.3.237. PubMed 23537458 ↗

Related links

• Clinical Trials at Novo Nordisk ↗